American Journal of Cardiology
Volume 103, Issue 7 , Pages 1032-1038, 1 April 2009

B-Type Natriuretic Peptides and Their Relation to Cardiovascular Structure and Function in a Population-Based Sample of Subjects Aged 70 Years

  • Kai M. Eggers, MD, PhD

      Affiliations

    • Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author: Tel: 46-18-611-00-00; fax: 46-18-50-66-38
  • ,
  • Bertil Lindahl, MD, PhD

      Affiliations

    • Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala, Sweden
  • ,
  • Per Venge, MD, PhD

      Affiliations

    • Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden
  • ,
  • Lars Lind, MD, PhD

      Affiliations

    • Department of Medical Sciences, Medicine, Uppsala University Hospital, Uppsala, Sweden

Received 19 October 2008; received in revised form 12 December 2008; accepted 12 December 2008. published online 09 February 2009.

The aim of the present study was to evaluate whether B-type natriuretic peptides (BNPs) could serve as screening markers for the detection of preclinical vascular disease in the community. BNP and N-terminal–pro-BNP were analyzed in 1,000 subjects aged 70 years participating in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study and were related to different measures of endothelial function and activation, arterial compliance, carotid atherosclerosis, and echocardiographic findings. The median levels were 42.0 ng/L for BNP and 110.7 ng/L for N-terminal–pro-BNP. On adjusted multivariate analysis, the 2 BNPs were related to increased left ventricular mass and impaired left ventricular systolic and diastolic function but not to any of the other assessed entities reflecting preclinical vascular disease. In conclusion, BNPs are strong markers of increased left ventricular mass and impaired cardiac performance but cannot be regarded as useful screening markers for the detection of preclinical states of vascular disease in elderly subjects.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Swedish Research Council, Stockholm, Sweden (Grant K2003-71X-00676-21A) and The Linné Foundation for Medical Research, Uppsala, Sweden. Dr. Lind received a research grant from AstraZeneca, Mölndal, Sweden.

PII: S0002-9149(08)02212-1

doi:10.1016/j.amjcard.2008.12.014

American Journal of Cardiology
Volume 103, Issue 7 , Pages 1032-1038, 1 April 2009